ArticleCell death & disease2026
CUL7-mediated KEAP1 ubiquitination promotes the progression of colon cancer via NRF2 signaling.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Cullin7 (CUL7) mediates cancer progression across multiple cancer types through its regulatory role in protein ubiquitination. However, the biological function and molecular mechanisms underlying CUL7 in colon cancer remain poorly defined. Here, we demonstrate that high CUL7 expression correlates with poor prognosis in patients. Ablation of CUL7 inhibited cell proliferation and migration in colon cancer cells, whereas CUL7 overexpression exhibited oncogenic properties. Moreover, Cul7-deplete mice exhibit a lower level of tumor growth. Mechanistically, CUL7 interacts with Kelch-like ECH-associated protein 1 (KEAP1) and catalyzes K29- and K48-linked polyubiquitination to promote its proteasomal degradation, which is crucial for NRF2 signaling. This leads to the decline of reactive oxygen species (ROS) and promotion of cancer growth. Importantly, the C-terminus of CUL7 is a crucial for governing KEAP1 stability and orchestrating antioxidant defense and cell growth. Clinical analysis identifies an inverse correlation between CUL7 and KEAP1 expression, and a positive correlation between CUL7 and NRF2 levels in human colon cancer. Our findings indicate that CUL7 mediates NRF2 signaling through promoting the KEAP1 ubiquitination, a mechanism that is integral to colon cancer progression. Collectively, these results establish CUL7 as a potential therapeutic target for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.